Allogeneic Car Nk Cell Therapy Articles & Analysis
62 news found
Healiva®, a patient-centric company delivering life-enhancing precision medicine for patients with chronic and acute wounds, announced today the acquisition of two innovative cell therapy assets from Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology business. The acquisition enables Healiva® to establish one of the world’s broadest portfolios of affordable, ...
Cartherics’ CEO, Professor Alan Trounson, was recently interviewed by CGTLive, to discuss the company’s development of NK cell, T-cell and macrophage cell therapies for various solid tumours. Cartherics is using its induced pluripotent stem (iPS) cell platform to develop NK cell, T-cell, and macrophage cell therapies with potential indications for solid tumour types including ...
Data support the potential of INB-100 to induce long-term durable responses in patients with high-risk or relapsed acute myeloid leukemia (AML). Clinical activity observed includes continuing robust durability of relapse-free survival; all three patients in Cohort 1 remain alive and progression-free; ongoing durations of response exceed 12 months and extend beyond 25 months. To date, INB-100 ...
All three patients from the first cohort of high-risk relapsed acute-myeloid leukemia (AML) patients dosed to-date with INB-100 remain alive and progression-free after at least one year. Patients remain in morphological complete remission (CR) with two patients over two years and a third over one year post-transplant, respectively. Safety profile continues to be manageable with no ...
Charles River Laboratories International, Inc. (NYSE: CRL) and ASC Therapeutics, a privately held biopharmaceutical company pioneering the development of transformative in vivo gene replacement, gene editing and allogeneic cell therapies, today announced they have agreed to manufacture ASC618, a second-generation gene therapy for hemophilia A. Hemophilia A is caused by the lack of the blood ...
“Together, the successful pairing of Umoja’s RACR™ engineered iPS cells and TreeFrog’s C-Stem™ technology could overcome several challenges facing ex vivo allogeneic therapies,” said Ryan Larson, Ph.D., Vice President and Head of Translational Science at Umoja. ...
(Nasdaq: CELU) (“Celularity”), a clinical-stage biotechnology company developing placental-derived off-the-shelf allogeneic cell therapies, today announced it is set to join the broad-market Russell 3000 and the Russell 2000 Indexes at the conclusion of the 2022 Russell indexes annual reconstitution, effective after the U.S. market ...
Phase 2 study completed enrollment ahead of schedule Posoleucel well-tolerated with no cases of graft rejection observed to date Overall decline in median BK viral load among patients completing 12 weeks of dosing with posoleucel or placebo (2:1 randomization) Posoleucel detected up to 12 weeks after last infusion Topline, unblinded study results from all 61 patients expected to be released ...
ByKalaris
(Nasdaq: CELU) (“Celularity”), a clinical-stage biotechnology company developing placental-derived off-the-shelf allogeneic cell therapies, today announced the appointment of Diane Parks to its Board of Directors. ...
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it has expanded its existing collaboration with Advanced BioMatrix, a division of BICO Group AB (STO: BICO), for Lineage’s HyStem cell/drug delivery technology. Under the expanded collaboration, Advanced ...
Capricor Expands Senior Management Team to Build Commercial Strategy for Lead Asset, CAP-1002, and Further Develop Partnering Strategy for Proprietary Exosome Platform Formerly at Edwards Lifesciences, Gilead and Genentech, Mr. Avat Brings Over 25 Years of Business and Commercial Strategy Experience to Capricor Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company focused on the ...
ASC Therapeutics, a privately held biopharmaceutical company pioneering the development of transformative in-vivo gene replacement, gene editing and allogeneic cell therapies has joined as a full partner the Accelerating Medicines Partnership® Bespoke Gene Therapy Consortium (AMP® BGTC) including the National Institutes of Health (NIH) and the Food and Drug Administration (FDA), managed ...
First known bovine model used to demonstrate safety and efficacy in gene replacement therapy MSUD is a severe genetic disease with liver transplantation or dietary restriction as the only treatments currently available ASC Therapeutics in partnership with the UMass Chan Medical School and the Clinic for Special Children (CSC), presented safety and efficacy results of a dual-function gene ...
Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, announced today that Dr. Linda Marbán, CEO of Capricor, will present at the H.C. Wainwright Global Investment Conference being held on May 23-26, 2022 in Miami, Florida. Please see ...
(Nasdaq: CELU) (“Celularity”), a clinical-stage biotechnology company developing placental-derived off-the-shelf allogeneic cell therapies, today announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the purchase and sale of 4,054,055 shares of its Class A common stock at ...
Podium presentation highlights significant transduction and transgene expression in pharmacokinetic studies in mice, non-human primates and a humanized liver model Poster presentation focuses on pharmacology, toxicology and safety studies Poster presentation focuses on the development of a novel transduction assay to evaluate in-vitro relative Infectivity ASC Therapeutics, a privately held ...
” First Quarter Clinical and Regulatory Updates CYNK-001 for the Treatment of AML and GBM: CYNK-001 is Celularity’s unmodified cryopreserved human placental hematopoietic stem cell-derived NK cell therapy candidate that is enriched with CD56+/CD3- NK cells and expanded from human ...
Executed Partnership with Nippon Shinyaku for the Commercialization and Distribution of CAP-1002 for Duchenne Muscular Dystrophy in the United States Upfront Payment of $30 Million Received in 1 st Quarter Strengthens Cash Position and Extends Cash Runway Positive Phase 2 Results Published in The Lancet Evaluating CAP-1002 in Late-Stage Duchenne Muscular Dystrophy Pivotal Phase 3 Trial ...
Initiated posoleucel registrational study to prevent six devastating viral infections and now enrolling high-risk allo-HCT patients in the U.S., Western Europe and Asia FDA granted RMAT designation to posoleucel for Phase 3 multi-virus prevention indication with an estimated annual addressable patient population of 40,000 allo-HCT patients Progressed enrollment in three Phase 3 studies for ...
ByKalaris
Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, will release its financial results for the first quarter ended March 31, 2022, after the market close on Tuesday, May 10, 2022. Management will then host a webcast and conference call at ...